AI Access Brief Podcast
AI Generated Daily briefings on HEOR, HTA strategy and the evidence access landscape. For pharmaceutical and biotech professionals navigating regulatory-payer alignment, HTA submissions, and evidence strategy.
AI Access Brief Podcast
CHMP Rare Disease Pipeline and NICE Threshold Implementation
Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.
Welcome to Access Brief, the daily AI podcast on HAUR, HTA, and Market Access. I'm Marcus with Sarah. Today, CHMP's rare disease approval momentum, nice threshold implementation details, and JCA capacity hitting hard limits. Let's get into it.
SPEAKER_00Starting with EMA, the CHMP recommended eight medicines for approval at its May meeting. But look at the pattern here, Marcus. This isn't random volume.
SPEAKER_01Agreed. The May session reinforces what we've been tracking. The CHMP is processing a pipeline skewed heavily toward rare, molecularly targeted, and specialty indications. For sponsors in those spaces, the committee has developed institutional fluency with small patient populations, surrogate endpoints, and conditional authorization pathways.
SPEAKER_00That institutional fluency is exactly the problem. We're seeing approval machinery optimized for rare diseases while common conditions get squeezed out. The evidence standards aren't getting more rigorous.
SPEAKER_01I don't buy that framing, Sarah. The CHMP is responding to where innovation actually lives right now. Yo, rare disease sponsors have learned to build dossiers that work within existing frameworks. That's not lowered standards. That's better evidence strategy.
SPEAKER_00Better evidence strategy for whom? We're creating a two-tier system where rare diseases get procedural advantages while high prevalence conditions face the same old evidence bars. That's a policy choice, not a scientific inevitability.
SPEAKER_01Moving to NICE, they've finally released implementation details for the threshold increase. All ongoing and new appraisals continue under the existing 20,000 pounds, 30,000 pounds range until April 2026. NICE will categorize ongoing topics into three groups with cost-effective products under current thresholds continuing as normal.
SPEAKER_00The transition mechanics matter less than the projected impact. NICE currently recommends 91% of medicines they evaluate, around 70 per year. Their analysis suggests the 25,000 pounds, 35,000 pounds threshold will allow them to recommend an additional three. Five new medicines or indications annually.
SPEAKER_01Five additional recommendations. Either NICE's current recommendation rate already captures most viable products, or this increase isn't as meaningful as the fanfare suggested.
SPEAKER_00Or it signals that NICE knows exactly where the real cost-effectiveness cliff sits. They're not opening floodgates, they're making targeted adjustments for products that were borderline under the old thresholds. It's surgical, not transformational.
SPEAKER_01That surgical approach makes sense given JCA constraints intensifying across Europe. The European Commission announced a maximum of 17 slots for scientific advice. 8, 12 for medicines, 2, 5 for medical devices. That's a hard capacity ceiling.
SPEAKER_00And medical device JCAs are starting in June with approximately five joint clinical assessments planned. We're watching HTA infrastructure strain in real time. The question isn't whether JCA will work, it's whether it can scale.
SPEAKER_01Here's where I push back on the scaling pessimism. Constrained capacity forces better prioritization. If we only get 17 scientific advice slots, sponsors will submit higher quality requests. Artificial scarcity can improve signal-to-noise ratios.
SPEAKER_00That assumes rational prioritization, Marcus. What we'll actually see is political allocation. Member states gaming the system for their national champions while genuinely innovative products get squeezed out by procedural bottlenecks.
SPEAKER_01ISPR 2026 highlighted a critical shift in how we think about evidence generation. AI topped the trends report rising from number three to number one, but the real insight came from the mandate change. We're no longer being evaluated on our ability to produce data. We're being judged on our ability to influence decisions under constraint.
SPEAKER_00That's the most important development this week. The HEOR field is maturing past data generation into decision architecture. Real-world evidence ranks second in iSport's trends, but it's not about having more data. It's about having the right data at the right decision point.
SPEAKER_01The constraint-driven approach forces discipline we've lacked. When HTA capacity is unlimited, you can throw evidence at every problem. When it's constrained, you have to understand which evidence actually moves decisions.
SPEAKER_00The danger is that constraint-driven thinking becomes constraint-accepting thinking. We should be building HTA systems that can handle innovation volume, not innovation rationing systems that make artificial scarcity seem efficient.
SPEAKER_01We're seeing HTA bodies acknowledge their limits while the industry adapts to work within them. That's not rationing. That's market clearing at a different equilibrium point.
SPEAKER_00Next week we'll show whether these capacity constraints are temporary growing pains or the new normal. The evidence suggests we're designing permanent limitations into European HTA infrastructure.
SPEAKER_01Back tomorrow on AccessBrief.no.